A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis.

Trial Profile

A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Moxifloxacin (Primary) ; Pretomanid (Primary) ; Isoniazid/rifampicin; Pyrazinamide; Rifampicin/isoniazid/pyrazinamide/ethambutol
  • Indications Tuberculosis
  • Focus Therapeutic Use
  • Acronyms STAND
  • Sponsors Global Alliance for TB Drug Development
  • Most Recent Events

    • 20 Dec 2016 Status changed from suspended to active, no longer recruiting.
    • 02 Nov 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 20 Jan 2015 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top